Addendum
Inebilizumab (immunoglobulin G4-related disease) – Addendum to Project A26-26
Report documents
-
Addendum
Inebilizumab (immunoglobulin G4-related disease) – Addendum to Project A26-26
Dossier assessment
Indication:
Adults with active immunoglobulin G4-related disease for whom long-term immunosuppressive treatment is an option
Result of dossier assessment:
unchanged after addendum: Added benefit not proven
Additional information
Federal Joint Committee (G-BA)
03-09-2026 A G-BA decision was published.
G-BA documents on this decision
Project details
- Project no.
- A26-97
- Commission
- Commission awarded on 28.07.2026 by the Federal Joint Committee (GBA).
- Report type
- Addendum
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Immune system and infections
- Note
-
If the need for additional work on a project commissioned by the GBA arises during consultations, IQWiG submits an addendum. The subsequent decides on the extent of the added benefit concludes the early benefit assessment.
- DOI
- https://doi.org/10.60584/A26-97
Connected Projects
-
Dossier assessment
Inebilizumab (immunoglobulin G4-related disease) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed